A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer

2024-514661-19-01 · tracked via the Priya Life Science EU tracker

Sponsor

Stemline Therapeutics Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

29/12/2025

Enrollment target

Sites

Spain

Condition studied

Advanced ER+/HER2- Breast Cancer

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-514661-19-01 on CTIS ↗ ← All trials in the EU